drugset
drugset / Trial / NCT02640729

Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

NCT02640729 ↗

Phase 2 Completed 30 enrolled Axovant Sciences Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study seeks to evaluate safety and efficacy of Nelotanserin for the treatment of visual hallucinations in subjects with Lewy body dementia.

Timeline

Start
2015-12
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelotanserin Small molecule 80 mg Oral

Indications

Charles bonnet syndrome Lewy body dementia